Are you looking to invest in the rapidly growing weight loss drug industry? Roundhill Investments’ GLP-1 & Weight Loss ETF (OZEM) might be the perfect opportunity for you. This new exchange-traded fund pairs leaders like Eli Lilly and Novo Nordisk with companies developing innovative treatments for weight loss and diabetes. CEO Dave Mazza believes that this industry has explosive growth potential, making it an attractive investment opportunity.
Eli Lilly and Novo Nordisk each hold a substantial 20% weighting in the ETF, with other key players like Zealand Pharma, Amgen, and Chugai Pharmaceutical also included. In the past year, Eli Lilly has seen a 90% increase in its stock price, while Novo Nordisk has gained 68%. Mazza is confident that the weight loss drug industry is still in its early stages, leaving plenty of room for growth and new entrants.
Comparing GLP-1 drugmakers to AI-linked stocks, Mazza sees similarities in the potential for significant growth. Just as Nvidia has dominated the AI industry, Eli Lilly and Novo Nordisk have established themselves as leaders in the weight loss drug market. Despite a slight dip in the ETF’s performance after its launch, experts remain optimistic about its long-term success.
At Extreme Investor Network, we believe in providing our readers with valuable insights and opportunities in the world of finance. Stay ahead of the curve and explore the potential of the weight loss drug industry with Roundhill Investments’ GLP-1 & Weight Loss ETF. Join us as we uncover the latest trends and investment opportunities for extreme returns.